These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 29337856)

  • 1. Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B.
    Ma Z; Cao Q; Xiong Y; Zhang E; Lu M
    Vaccines (Basel); 2018 Jan; 6(1):. PubMed ID: 29337856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.
    Ma Z; Zhang E; Yang D; Lu M
    Cell Mol Immunol; 2015 May; 12(3):273-82. PubMed ID: 25418467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection.
    Du Y; Wu J; Liu J; Zheng X; Yang D; Lu M
    Front Immunol; 2022; 13():965018. PubMed ID: 35967443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection.
    Zhang E; Lu M
    Med Microbiol Immunol; 2015 Feb; 204(1):11-20. PubMed ID: 25550115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells.
    Wu J; Meng Z; Jiang M; Pei R; Trippler M; Broering R; Bucchi A; Sowa JP; Dittmer U; Yang D; Roggendorf M; Gerken G; Lu M; Schlaak JF
    Hepatology; 2009 Apr; 49(4):1132-40. PubMed ID: 19140219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-Like Receptor Response to Hepatitis B Virus Infection and Potential of TLR Agonists as Immunomodulators for Treating Chronic Hepatitis B: An Overview.
    Kayesh MEH; Kohara M; Tsukiyama-Kohara K
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways.
    Pei RJ; Chen XW; Lu MJ
    World J Gastroenterol; 2014 Sep; 20(33):11618-29. PubMed ID: 25206268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in different interactions between toll-like receptors and hepatitis B infection: a review.
    Soleiman-Meigooni S; Yarahmadi A; Kheirkhah AH; Afkhami H
    Front Immunol; 2024; 15():1363996. PubMed ID: 38545106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver.
    Suslov A; Boldanova T; Wang X; Wieland S; Heim MH
    Gastroenterology; 2018 May; 154(6):1778-1790. PubMed ID: 29408639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells.
    Guo H; Jiang D; Ma D; Chang J; Dougherty AM; Cuconati A; Block TM; Guo JT
    J Virol; 2009 Jan; 83(2):847-58. PubMed ID: 18971270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-Activation of Toll-Like Receptor 2 Enhances CD8
    Lin Y; Huang X; Wu J; Liu J; Chen M; Ma Z; Zhang E; Liu Y; Huang S; Li Q; Zhang X; Hou J; Yang D; Lu M; Xu Y
    Front Immunol; 2018; 9():1495. PubMed ID: 30008718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy.
    Chang J; Block TM; Guo JT
    Antiviral Res; 2012 Dec; 96(3):405-13. PubMed ID: 23072881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating the innate immune response to counter chronic hepatitis B virus infection.
    Lamb C; Arbuthnot P
    Expert Opin Biol Ther; 2016 Dec; 16(12):1517-1527. PubMed ID: 27603796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice.
    Wu J; Lu M; Meng Z; Trippler M; Broering R; Szczeponek A; Krux F; Dittmer U; Roggendorf M; Gerken G; Schlaak JF
    Hepatology; 2007 Dec; 46(6):1769-78. PubMed ID: 17929296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate immune targets of hepatitis B virus infection.
    Zou ZQ; Wang L; Wang K; Yu JG
    World J Hepatol; 2016 Jun; 8(17):716-25. PubMed ID: 27330680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of microRNA-155 correlates positively with the expression of Toll-like receptor 7 and modulates hepatitis B virus via C/EBP-β in hepatocytes.
    Sarkar N; Panigrahi R; Pal A; Biswas A; Singh SP; Kar SK; Bandopadhyay M; Das D; Saha D; Kanda T; Sugiyama M; Chakrabarti S; Banerjee A; Chakravarty R
    J Viral Hepat; 2015 Oct; 22(10):817-27. PubMed ID: 25720442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus genome replication triggers toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen.
    Real CI; Lu M; Liu J; Huang X; Trippler M; Hossbach M; Deckert J; Jahn-Hofmann K; Ickenstein LM; John MJ; Gibbert K; Dittmer U; Vornlocher HP; Schirmbeck R; Gerken G; Schlaak JF; Broering R
    Sci Rep; 2016 Apr; 6():24865. PubMed ID: 27121087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms of toll-like receptors and their pathways in viral hepatitis.
    Sawhney R; Visvanathan K
    Antivir Ther; 2011; 16(4):443-58. PubMed ID: 21685532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.